BMX
MOLECULAR TARGETBMX non-receptor tyrosine kinase
BMX (BMX non-receptor tyrosine kinase) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting BMX
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | ibrutinib | 4.86 | 128 |
| 2 | foretinib | 4.34 | 76 |
| 3 | tozasertib | 4.33 | 75 |
| 4 | bosutinib | 4.08 | 58 |
| 5 | canertinib | 3.53 | 33 |
| 6 | pelitinib | 3.50 | 32 |
| 7 | tae 684 | 3.43 | 30 |
| 8 | fedratinib | 3.40 | 29 |
| 9 | mln 8054 | 3.33 | 27 |
| 10 | acalabrutinib | 3.22 | 24 |
| 11 | jnj 7706621 | 3.09 | 21 |
| 12 | lestaurtinib | 3.04 | 20 |
| 13 | spebrutinib | 3.04 | 20 |
| 14 | r 406 | 2.83 | 16 |
| 15 | infigratinib | 2.77 | 15 |
| 16 | ritlecitinib | 2.77 | 15 |
| 17 | kw 2449 | 2.64 | 13 |
| 18 | ast 487 | 2.56 | 12 |
| 19 | zanubrutinib | 2.56 | 12 |
| 20 | evobrutinib | 2.48 | 11 |
| 21 | rebastinib | 2.20 | 8 |
| 22 | tirabrutinib | 1.95 | 6 |
| 23 | anilinopyrimidine1 | 1.79 | 5 |
| 24 | Crizotinib | 0.69 | 1 |
| 25 | bdb pf 06651600 us11111242 example 5 us9617258 example 5 | 0.69 | 1 |
About BMX as a Drug Target
BMX (BMX non-receptor tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented BMX interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
BMX inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.